Browse RNASET2

Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Lysosome lumen. Endoplasmic reticulum lumen. Note=Subcellular fractionation of transfected ovarian cancer cells reveals full-length RNASET2 in the endoplasmic reticulum fraction and the 2 smaller RNASET2 proteolytic products in the lysosome fraction.
Domain PF00445 Ribonuclease T2 family
Function

Has ribonuclease activity, with higher activity at acidic pH. Probably is involved in lysosomal degradation of ribosomal RNA (By similarity). Probably plays a role in cellular RNA catabolism.

> Gene Ontology
 
Biological Process GO:0006401 RNA catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046700 heterocycle catabolic process
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0090501 RNA phosphodiester bond hydrolysis
GO:0090502 RNA phosphodiester bond hydrolysis, endonucleolytic
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0004518 nuclease activity
GO:0004519 endonuclease activity
GO:0004521 endoribonuclease activity
GO:0004540 ribonuclease activity
GO:0016892 endoribonuclease activity, producing 3'-phosphomonoesters
GO:0016894 endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters
GO:0033897 ribonuclease T2 activity
Cellular Component GO:0005775 vacuolar lumen
GO:0005788 endoplasmic reticulum lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNASET2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RNASET2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23630276Ovarian CarcinomaPromote immunity (infiltration)Indeed, hyperexpression of RNASET2 is able to control tumorigenesis by recruiting macrophages (mostly of the anticancer M1 subtype) at the tumor sites.
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNASET2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNASET2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3750.296
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.80.752
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0750.97
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0290.951
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0340.986
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0270.991
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1790.685
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.190.901
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1230.944
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1380.643
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9550.807
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0010.995
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNASET2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNASET2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNASET2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNASET2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNASET2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNASET2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNASET2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNASET2
Nameribonuclease T2
Aliases RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNASET2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.